Published in final edited form as:
J Nat Prod. 2007 May ; 70(5): 741–746. doi:10.1021/np060489v.

Halogenated Cyclic Peptides Isolated From the Sponge *Corticium* sp

Damian W. Laird[†], **Daniel V. LaBarbera**[†], **Xidong Feng**[‡], **Tim S. Bugni**[†], **Mary Kay Harper**[†], and **Chris M. Ireland**[*,†]

Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT, 84103, Wyeth Research, Pearl River, NY, 10965 cireland@pharm.utah.edu

Abstract

Fractionation of two Fijian specimens of the sponge *Corticium* sp., led to the isolation of the known active alkaloid steroid plakinamine A and two new halogenated cyclic peptides, corticiamide A (**1**) and cyclocinamide B (**2**). Structural elucidation of **1** and **2** was achieved by an extensive combination of high field NMR and HRFT MS/MS experiments, and the absolute stereochemistry of **2** was determined by acid hydrolysis and Marfey's analysis. Corticiamide A (**1**) and cyclocinamide B (**2**) represent the first peptides to be described from the genus *Corticium.*

The sponge genus *Corticium* is widespread in warm temperate to tropical waters of the world's oceans, yet compounds isolated from the genus are far from prevalent within the chemical literature. To date, only two main structural motifs have been reported: the polycyclic meridene[1] and a number of steroidal alkaloids, including members of the plakinamine family[2–6] and two unusual steroids containing a seven membered B ring.[7] Almost all reported *Corticium* derived compounds have exhibited *in vitro* bioactivity. For example, meridene is a potent antifungal compound,[1] plakinamine derivatives exhibit significant *in vitro* cytotoxic activity[6] and slight HIV activity,[5] and the lokysterolamines have been reported to be cytotoxic, antimicrobial and antifungal agents.[2] Recently, an additional class of steroidal alkaloids from *Corticium simplex* has been described that shows anti-proliferative activity as well as antiangiogenic activity.[8] Fractionation of *Corticium* sp. collected from Fiji in the years 2001–2004 inclusive, led to the isolation of plakinamine A and two new cyclic peptides, corticiamide A (**1**) and cyclocinamide B (**2**). Structural elucidation of the two new peptides was achieved by extensive use of NMR and FTMS/MS experiments, and the absolute stereochemistry of cyclocinamide B (**2**) was determined by Marfey's analysis. Corticiamide A (**1**) and cyclocinamide B (**2**) are the first peptides, and the first halogenated compounds, to be isolated from a species of *Corticium*.

Results and Discussion

The crude methanol extract of the 2002 collection of the Fijian *Corticium* sp. was partitioned between EtOAc and H_2O, and the bioactive EtOAc soluble material was separated on HP20 resin resulting in 5 fractions. Fraction 3 was the most active and was separated by HPLC yielding 0.8 mg of corticiamide A (**1)** as a pale yellow oil. Monoisotopic peaks for the doubly charged molecular ions $[M+2H]^{2+}$ and $[M+H+Na]^{2+}$ were detected at *m/z* 948.32495 and *m/z* 959.31633 in positive mode nanoelectrospray FTMS corresponding to a neutral monoisotopic

*To whom Correspondence should be addressed. Tel: 801 581 8305, FAX: 801 585 6208.
[†]University of Utah
[‡]Wyeth Research

mass of 1894.63617. On the basis of accurate mass measurements of the molecular and fragment ions, a molecular formula of $C_{80}H_{112}Br_2N_{20}O_{22}S$ was determined for the neutral molecule.



Interpretation of 1D and 2D NMR spectra (^{1}H, TOCSY, gHSQC and gHMBC) resulted in the identification of 14 partial structures. Eight standard amino acid residues were identified as Ala, Val, two Thr, Pro, Trp, Gly, and Arg. In addition, a formamide moiety was determined by the presence of a signal in the HSQC spectrum for a methine with shifts at δ_H 7.89 and δ_C 161.2, respectively. The presence of two ortho-coupled proton signals at δ_H 7.25 and δ_H 7.40 in the ^{1}H NMR spectrum suggested a *para* substituted phenyl ring. Correlations in the HMBC spectrum from the ortho-coupled aromatic protons to two quaternary carbons (δ_C 120.2 and δ_C 137.6) suggested a *p*-Br substitution. TOCSY correlations from an *N*H (δ_H 7.94) to a methine at δ_H 4.73 and a diastereotopic methylene (δ_H 2.73, δ_H 3.01; δ_C 38.8), in combination with an HMBC correlation from this methylene to aromatic carbons (δ_C 132.5 and δ_C 137.6) established this residue as *p*-Br-Phe. A second *p*-Br-Phe residue was identified in a similar manner. The cysteic acid residue was proposed based on the downfield ^{13}C chemical shifts (δ_C 51.6 and δ_C 53.0, respectively) of an observed *N*H-CH-CH_2 spin system and was confirmed by MS studies (*vide infra*). The β-Me-Ile residue was determined by HMBC correlations from an sp^3 hybridized quaternary carbon (δ_C 37.5) to three methyl groups, one of which had an upfield ^{13}C shift at δ_C 8.7, a methylene, and an *N*H-CH. An *N*-Me-Gln was identified starting from an HMBC correlation between an *N*-methyl (δ_H 2.93, δ_C 30.5) and a methine (δ_C 54.9) that was part of a -CH-CH_2-CH_2- TOCSY spin system. An HMBC correlation from the γ-methylene to the δ-carbonyl (δ_C 174.0) provided additional support for the *N*-Me-Gln. An HMBC correlation from a second *N*-methyl (δ_H 2.60, δ_C 29.2) to a methine (δ_C 56.7) that was part of a -CH_2-CH_2- spin system was consistent with an *N*-Me-Asn. HMBC correlations from the methylene protons (δ_H 2.34, δ_H 2.84) to the γ-carbonyl (δ_C 171.5) confirmed the presence of *N*-Me-Asn. The linear sequence of (**1**) was deduced from inter-residue ROESY correlations (see Figure 1) in conjunction with MS experiments.

Attempts to confirm the structure using ESI FTMS/MS experiments were conducted concurrently with the NMR based structure elucidation. FTMS/MS experiments using Sustained Off-Resonance Irradiation with Collision Induced Dissociation (SORI-CID) were crucial to solving the planar structure of **1** as it enabled accurate mass measurements of MS/MS daughter ions, resulting in the assignment of specific molecular formulas for many fragments.[9] The SORI-CID mass spectrum of the isolated $[M+2H]^{2+}$ at *m/z* 948 is shown in Figure 2. The majority of the fragmentation occurred in the linear region of the peptide, and the most abundant fragment ion (*m/z* 786^{2+}) was produced through cleavage of the amide bond on the *N*-terminal side of the Pro residue. Cleavage *N*-terminal to a Pro residue has been widely observed and documented as the major fragmentation site for many peptides,[10] and the

fragmentation pattern observed provides support for the assignment of a Pro at residue 3. The neutral loss between *m/z* 948 ($[M+2H]^{2+}$) and *m/z* 786^{2+} could be assigned the elemental composition $C_{13}H_{13}BrN_2O_3$ corresponding to HCO-Ala-*p*Br-Phe. The Pro residue could be unambiguously assigned by the observation of the b_3 ion. Detection of the b_4 and b_5 ions, together with their complementary y_{10}'' and y_9'' ions, resulted in the sequence assignment of a β-MeIle-Val fragment after the Pro residue. Unique elemental compositions were determined based on accurate mass measurements for these relatively small b_3, b_4, and b_5 fragment ions and were supported by an observed isotopic distribution characteristic of the presence of one Br atom. The sequence was easily extended to Trp and Arg based upon the y-series fragment ions. Unique elemental compositions could not be determined for these relative large y-series fragment ions, but the mass difference between adjacent y-series fragment ions was easily assigned a unique elemental composition based upon accurate mass measurements.

The peptide sequence could not be followed after Arg using fragmentation of the molecular ion, as neither b_8 nor its complementary y_6'' ion (cleavage of $CysO_3H$-Thr) was detected in the positive mode FTMS SORI-CID mass spectrum. Therefore, the abundant doubly charged y_{12}'' ion, *m/z* 786^{2+}, was isolated and fragmented using SORI-CID. Although the sequence immediately after Arg could not be determined, due again to the lack of fragment ions from the cleavage of $CysO_3H$-Thr, the connection of Gly-*N*MeAsn-Thr-*p*BrPhe-*N*MeGln was established by detection of the following series of ions: *m/z* 143.08176 ($C_6H_{11}N_2O_2^{1+}$), 368.06100 ($C_{15}H_{19}BrN_3O_3^{1+}$), 469.10886 ($C_{19}H_{26}BrN_4O_5^{1+}$), 597.16707 ($C_{24}H_{34}BrN_6O_7^{1+}$), and 654.18813 ($C_{26}H_{37}BrN_7O_8^{1+}$). Once again, unique elemental compositions were determined for each ion based upon observed accurate mass measurements for these relatively small fragment ions and supported by the detected isotopic distribution (four of them are characteristic of one Br atom). Complementary ions to the *m/z* 469 and 597 ions were also detected at *m/z* 1103.53108 ($C_{48}H_{75}N_{14}O_{14}S^{1+}$) and 975.47237 ($C_{43}H_{67}N_{12}O_{12}S^{1+}$), respectively, further supporting the proposed sequence connection. Detailed examination of the SORI-CID mass spectrum for the isolated *m/z* 786^{2+} ion indirectly suggested the presence of a $CysO_3H$-Thr fragment. Firstly, the elemental composition for the difference between the two major fragment ions *m/z* 666 and 975 could be assigned as $C_9H_{15}N_3O_7S$ (Expt, 309.06370, Calcd 309.06307, Δ = 0.63 mmu) corresponding to $CysO_3H$-Thr-Gly, and secondly, the observed *m/z* 818 ion could be explained as the loss of SO_3H_2 from the *m/z* 900 ion, which itself could be explained as resulting from the *m/z* 975 ion by the loss of Gly and H_2O.

Assignment of $Cys(O_3H)$ adjacent to Arg was made unambiguously by the detection of the $y_6''^{1-}$ ion in the SORI-CID mass spectrum of the isolated singly charged deprotonated molecular ion at *m/z* 1893^{1-}. The difference between *m/z* 753^{1-} (y_6'') and *m/z* 904^{1-} (y_7'') was accurately measured, resulting in a unique elemental composition corresponding to $Cys(O_3H)$. The peptide sequence in the linear portion of **1**, determined based on FTMS/MS of the doubly charged protonated $[M+2H]^{2+}$ molecular ion, was identical to that based on the FTMS/MS of the singly charged deprotonated $[M-H]^{1-}$ molecular ion, providing additional support for the sequence assignment.

Both MS and NMR data supported the linear sequence of **1**. However, the molecular formula assigned demanded 34 units of unsaturation and only 33 were accounted for above, which implied the presence of an additional ring. The chemical shift for the β-proton of Thr-1 was shifted downfield to δ_H 5.22, typical of a threonine involved in an ester linkage,[11–15] suggesting the site of cyclization. Observation of an HMBC correlation from the β-proton of Thr-1 to the Gly amide carbon (δ_C 169.0) confirmed that **1** was a cyclic depsipeptide.

Corticiamide A (**1**) is a member of a family of structurally related peptides that include the discodermins,[16–18] halicylindramides,[19,20] polydiscamide A[21] and microspinosamide A.

[22] However, corticiamide A (**1**) is the only member of the family to contain a *p*-Br-Phe at residue 11, and no other examples are known to contain an *N*-Me-Asn. Microspinosamide A and polydiscamide A contain the unusual β-Me-Ile at residue 6, whereas the same amino acid is found at residue 5 in **1**. Based upon these differences, the trivial name corticiamide A is proposed for **1**. All previously reported compounds in this class have a mixture of D and L amino acids. Unfortunately, due to the small amount of **1** isolated, the absolute stereochemistry of the molecule was not determined nor was the bioactivity evaluated.

The crude methanol extract of a 2001 collection of *Corticium* was partitioned (see Experimental), and the $CHCl_3$ soluble portion was separated using C_{18} flash chromatography (H_2O to CH_3OH gradient) resulting in thirteen fractions. While preparing fraction 10 for preliminary ^1H NMR analysis, a portion of the material was not soluble in CD_3OD and further investigation revealed that this waxy white substance was soluble in DMSO. The ^1H and ^{13}C NMR spectra of the DMSO soluble material indicated that the compound was of high purity, and a full structural elucidation was undertaken. The combination of six carbonyl signals in the range δ 169.4 to δ 173.5 in the ^{13}C spectrum (Table 2), typical of amide carbonyls suggested that compound (**2)** was most likely a peptide.

The mass spectrum obtained with ESI-FTMS indicated that the compound contained multiple halogens and SORI-CID experiments on the isolated monoisotopic molecular ion as well as the daughter ion *m/z* 535 established the molecular formula of **2** as $C_{29}H_{32}N_9O_8BrCl_2$ using the top-down, bottom-up approach (expt. 784.10084, calc. 784.10070).[9] Analysis of 1D and 2D NMR data (^1H, ^{13}C, COSY, TOCSY, gHSQC-TOCSY, gHSQC and gHMBC) led to the identification of six partial structures. A singlet at δ_H 11.1 and an upfield quaternary carbon at 111.8 suggested a 5-Br tryptophan residue (5-Br-Trp). Comparison with published data[23–25] confirmed the assignment of the 5-Br-Trp. HSQC-TOCSY correlations from the methine carbon at δ_C 70.4 (δ_H 4.04) to an *N*H (δ_H 7.05), a diastereotopic methylene (δ_H 3.35, δ_H 3.48), and a hydroxyl (δ_H 6.00) indicated the presence of isoserine (iSer). TOCSY correlations were used to establish a spin system incorporating *N*H-CH_2-CH-*N*H resulting in the assignment of a 1,2-diaminopropionic acid (DAP) residue. Using these spin systems for a database search resulted in cyclocinamide A (**3**). A comparison of NMR data in conjunction with the MS data indicated that cyclocinamide B (**2**) contained a dichloropyrrole instead of the monochloropyrrole found in cyclocinamide A (**3**). HMBC correlations from the aromatic methine singlet at δ 7.02 to the high-field carbonyl (δ 161.0), and two quaternary carbons (δ 125.2 and δ 119.2), established the aromatic methine at position 3 of the pyrrole, and the upfield ^{13}C chemical shift (δ 112.2) suggested an adjacent Cl substitution. Thus, the second Cl was located at position 5 on the pyrrole, leading to the elucidation of an *N*-Me-2-carbonyl-4,5-dichloropyrrole moiety.

Since cyclocinamide A (**3**), which was isolated from *Psammocinia* sp.,[26] is so similar to **2**, the trivial name cyclocinamide B is proposed for **2**. The published ^1H NMR spectrum of cyclocinamide A (**3**) and cyclocinamide B (**2**) are almost identical, further supporting the proposed structure for cyclocinamide B (**2**). The only major difference is the iSer OH, which Clark *et al*. assigned at δ 3.27. However, in cyclocinamide B (**2**) correlations in the HSQC-TOCSY and HMBC spectra clearly indicate that the doublet at 6.00 can be δ_H assigned to this hydroxyl. Most likely, the shift may vary and is dependent on the sample preparation (H_2O content, pH, etc.).

As a result of limited material Clark *et al*.[26] were only able to determine the absolute stereochemistry at two of the four stereocenters of cyclocinamide A (**3**). Using a combination of acid hydrolysis and chiral TLC they assigned *S* stereochemistry for the Br-Trp and Arg residues and suggested that, based upon biosynthetic considerations, the stereochemistry of the DAP and iSer residues should also be *S*. Although, synthesis of 4*R*, 11*R* cyclocinamide A

resulted in a product with a similar ^{1}H NMR, the spectrum was not identical to the natural product.[27]

Cyclocinamide B (**2**) was subjected to acid hydrolysis as described by Clark *et al*.[26] However, these conditions proved too harsh and resulted in complete decomposition. Complete hydrolysis was achieved at 110 °C in four hours with 6 N HCl in the presence of 0.1% phenol (to preserve the 5-Br-Trp residue). The hydrolysate was subjected to derivatization with *N*α-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (L-FDAA) and subsequent analysis by HPLC (Marfey's analysis).[28,29] Reference compounds were prepared with commercially available amino acids utilizing both pure L-amino acids and DL- mixtures. In each case the L-amino acid derivatives eluted before the D isomers. The results of the Marfey's analysis unambiguously proved the absolute stereochemistry for three of the four amino acids: D-Asp, L-DAP, and D-5-Br-Trp. Unfortunately, the retention times of L-FDAA-D-iSer and L-FDAA-Gly overlapped. To circumvent this problem, LCMS analysis of the *N*α-(2,4-dinitro-5-fluorophenyl)-L-valinamide (L-FDVA) derivatized amino acids was undertaken. The greater lipophilicity of L-FDVA vs. L-FDAA allowed for longer retention times and better separation. A coinjection with an L-FDVA-DL-iSer reference and the L-FDVA derivatized hydrolysate of **2** showed an enhancement of L-iSer over D-iSer and confirmed the presence of L-iSer in cyclocinamide B (**2**).

Both corticiamide A (**1**) and cyclocinamide B (**2**) have close structural resemblances to peptides isolated from sponges that are only distantly related, taxonomically, to *Corticium*. Thus, it seems likely that these two cyclic peptides may be produced by microorganisms associated with the Fijian *Corticium* sp.

Peptides related to corticiamide A (**1**), namely the discodermins, halicylindramides, polydiscamide A and microspinosamide A are all known to be cytotoxic in the low μM range and to inhibit the growth of bacteria and fungi.[17–22] In addition, microspinosamide A has been shown to inhibit the cytopathic effect of HIV-1 in CEM-SS cells.[22] Interestingly, the cyclic nature of these peptides is crucial to their bioactivity, with linear versions exhibiting a loss of activity of at least one order of magnitude. It has been noted that this class of peptides exhibits a high degree of amphiphilic character and that this may lead to observed increases in the membrane permeability of cells and tissues treated with discodermin A.[30] Cyclocinamide A (**3**) was reported to be highly cytotoxic *in vitro* and exhibited selective cytoxicity toward solid tumors in the soft agar colony formation disk diffusion assay; however, cyclocinamide B (**2**) had no cytotoxicity against HCT-116 cells.

Experimental Section

General Experimental Procedures

Optical rotations were measured on a Jasco DIP-370 polarimeter. UV spectra were obtained using a Perkin Elmer UV/VIS spectrometer Lambda2. IR spectra were recorded on a JASCO FTIR-420 spectrophotometer. NMR data for **1** were collected using either a Varian INOVA 500 (^{1}H 500 MHz, ^{13}C 125 MHz) NMR spectrometer with a 3 mm Nalorac MDBG probe or a Varian INOVA 600 (^{1}H 600 MHz, ^{13}C 150 MHz) NMR spectrometer equipped with a 5 mm ^{1}H[^{13}C,^{15}N] triple resonance cold probe with a z-axis gradient and utilized residual solvent signals for referencing (δ_H 1.94, δ_C 118.3 for CD_3CN). NMR data for **2** were obtained using a Varian Mercury 400 (^{1}H 400 MHz, ^{13}C 100 MHz) instrument equipped with a 5 mm Nalorac probe and utilized residual solvent signals for referencing (δ_H 2.49, δ_C 39.7 for DMSO-d_6). LCMS analyses were conducted with a Micromass Q-Tof micro mass spectrometer and a Waters 2795 HPLC. High resolution mass spectra (HRMS) were obtained using a Bruker (Billerica, MA) APEXII FTICR mass spectrometer equipped with an actively shielded 9.4 Tesla superconducting magnet (Magnex Scientific Ltd., UK), an external Bruker APOLLO

ESI source, and a Synrad 50W CO_2 CW laser. Nanoelectrospray in both positive and negative modes was employed. Typically, a 5 μL sample was loaded into the nanoelectrospray tip (New Objective, Woburn, MA) and a high voltage, about 1000 V, was applied between the nanoelectrospray tip and the capillary. Mass spectra were internally/externally calibrated using HP tuning mix. For FTMS/MS experiments, precursor ions were isolated using correlated sweep and then dissociated using SORI-CID. Analytical and semi-preparative HPLC was accomplished utilizing a Beckman System Gold 126 solvent module and 168 PDA detector. All commercially available reagents and amino acid standards were purchased and used without additional purification.

Biological Material

Corticium sp. was collected by SCUBA. Bulk material was frozen at −4°C until return to The University of Utah where it was stored at −20 °C until required. All of our Fijian collections of *Corticium* sp. (Homosclerophorida, Plakinidae) are morphologically indistinguishable. It is a common undescribed species of *Corticium* with a widespread Indo-Pacific distribution. The sponge is encrusting, contracting considerably after collection; it has a black exterior and slighter lighter interior. Sample FJ01-2-014 was collected in the lower Yasawa group (S 18° 42.041′ E 178° 30.309′), sample FJ02-13-059 was from the Great Astrolabe Reef (S 17° 10.211′ E 177° 17.720′); voucher specimens are maintained at the University of Utah.

Extraction and Isolation

Frozen sponge (70 g wet weight) from the 2002 collection (sample FJ02-13-059) was extracted with MeOH and the solvent removed *in vacuo*. The crude extract was then partitioned between EtOAc and H_2O and the EtOAc extracts were further separated on HP20ss resin (H_2O to MeOH in 25% steps, 10 mL fractions). The fraction eluting with 1:1 H_2O:MeOH was subjected to multiple rounds of RPHPLC as follows. Isocratic 2:3 MeOH:H_2O for 20 min, followed by a gradient to 100% MeOH over 40 min, 3.5 mL/min, Phenomenex phenylhexyl, 10 × 250 mm. The fraction that eluted with 80–85% MeOH contained corticiamide A (**1**) and was subjected to RPHPLC employing a gradient of 1:1 CH_3CN:H_2O to 4:1 CH_3CN:H_2O in 20 min, 3.5 mL/min, Phenomenex C_{18}, 10 × 250 mm. The corticiamide A (**1**) containing fraction eluted with 52–56% CH_3CN, and was subjected to a gradient from 3:7 CH_3CN:0.1% aq. TFA to 3:2 CH_3CN:0.1% aq. TFA over 20 min, and then to 100% CH_3CN in 5 min. Corticiamide A (**1**, 0.8 mg) eluted at 15 min.

Frozen sponge (100 g wet weight) from the 2001 collection (sample FJ01-2-014) was extracted with MeOH and the solvent removed *in vacuo*. The crude extract was then dissolved in 100 mL of 10% aqueous MeOH and extracted with hexanes (3 × 100 mL). An additional 35 mL of H_2O was added to the aqueous MeOH and extracted with $CHCl_3$ (3 × 100 mL). The $CHCl_3$ fraction was further separated by RP C_{18} flash chromatography using a H_2O:MeOH gradient in 10% steps. Fraction 10 contained 9.6 mg of **2**.

Corticiamide A (1)— $[\alpha]_D^{21}$+5 (*c* 0.16, MeOH); UV (MeOH) λ_{max} nm (log ε) 201 (4.59), 230 (4.23), 275 (3.5); IR (KRS-5 cell, DMSO) ν_{max} 3465, 2971, 1662, 1250, 1005 cm^{-1}; ^1H and ^{13}C NMR data, see Table 1; HRESIMS $[M+2H]^{2+}$ *m/z* 948.32495 (calcd 948.32465 for $C_{80}H_{114}Br_2N_{20}O_{22}S^{2+}$), $[M+H+Na]^{2+}$ *m/z* 959.31633 (calcd 959.31562 for $C_{80}H_{113}Br_2N_{20}NaO_{22}S^{2+}$).

Cyclocinamide B (2)— $[\alpha]_D^{21}$ +9.6 (*c* 0.033, MeOH); UV (MeOH) λ_{max} nm (log ε) 201 (3.53), 274 (2.43) IR (KRS-5 cell, DMSO) ν_{max} 3436, 2973, 2480, 1661, 1372, 1251, 1030, 602 cm^{-1}; ^1H and ^{13}C NMR data, see Table 2; HRESIMS *m/z* 784.10084 (calcd 784.10070 for $C_{29}H_{32}N_9O_8BrCl_2^{1+}$).

Acid Hydrolysis and FDAA Analysis of Cyclocinamide B (2)

To a thick walled micro vial containing 100 μg (0.13 μmoles) of **2** was added 250 μL of 6 N HCl containing 0.1 % phenol (w/v). The vial was sealed and heated at 110 °C for four hours. The reaction was allowed to cool to room temperature and was concentrated to dryness. The resulting dry residue was dissolved in 100 μL of water, and subsequently 300 μL of 1 M aqueous $NaHCO_3$ was added followed by 250 μL of a 1% solution of L-FDAA in acetone (w/v). This mixture was heated at 50 °C for 1.5 h, cooled to room temperature, and diluted with an equal volume of CH_3CN. The L-FDAA derivatives were separated by HPLC (1.0 mL/min, Phenomenex C_{18}, 5 μ, 4.6 × 250 mm) using a linear gradient of 10% CH_3CN in 0.1 M NH_4OAc (pH=5) to 50% CH_3CN in 0.1 M NH_4OAc over 60 min. The absolute stereochemistry was determined by comparing retention times of L and D, L amino acid standards derivatized with L-FDAA and the derivatized hydrolysate of **2**. HPLC retention times in min for the amino acid standards: L-Asp (10.9), D-Asp (13.6), L-iSer (19.9), D-iSer (20.6), Gly (20.4), L-DAP (39.3), D-DAP (40.3), L-5-BrTrp (39.6), D-5-BrTrp (43.3). HPLC retention times in min for L-FDAA derivatized amino acids of **2:** D-Asp (13.9), L-DAP (39.2), D-5-BrTrp (42.5).

FDVA derivatization of the hydrolysate of cyclocinamide B (2)

The hydrolysate of 2 was obtained as described above and was concentrated to dryness and dissolved in 75 μL of H_2O. Subsequently, 25 μL of 1 M aqueous $NaHCO_3$ was added followed by the addition of 100 μL of a 1% solution of L-FDVA in acetone (w/v). The reaction was heated at 40 °C for 1 h, and then neutralized with 20 μL of 1 N HCl.

LCMS analysis of the FDVA derivatives

The separation of L and D, L FDVA derivatives utilized a 2 × 50 mm, 3 μ, Phenomenex C18 column at 20 °C. A linear gradient (0.2 mL/min) using 0.1% acetic acid/99% CH_3CN to 100% CH_3CN over 75 min was used. The retention times in min for the reference D and L-iSer-L-FDVA: L-iSer (32), D-iSer (33). The retention time for L-FDVA derivatives of (**2**): L-iSer (31.9). Additionally, a coinjection with a 1:4 mixture of DL-iSer-L-FDVA standards to L-FDVA derivatives of (**2**) showed an enhancement of the peak corresponding to L-FDVA-L-iSer.

HCT-116 cytotoxicity assay

The assay was performed as previously described.[31]

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors are grateful to J. J. Skalicky for help in obtaining NMR data and would like to thank Drs. G. T. Carter and F. E. Koehn for their kind support. The authors would like to acknowledge the NIH, RR06262 and RR14768, and NSF grant DBI-0002806 for funding NMR instrumentation in the University of Utah Health Sciences NMR facility. This research was funded by NIH grant CA 067786.

References and Notes

1. McCarthy PJ, Pitts TP, Gunawardana GP, Kelly-Borges M, Pomponi S. J Nat Prod 1992;55:1664–1667. [PubMed: 1479383]
2. Jurek J, Scheuer PJ. J Nat Prod 1994;57:1004–1007. [PubMed: 7964780]
3. De Marino S, Iorizzi M, Zollo F, Roussakis C, Debitus C. Eur J Org Chem 1999;3:697–701.
4. Lee HS, Seo Y, Rho JR, Shin J, Paul VJ. J Nat Prod 2001;64:1474–1476. [PubMed: 11720539]

5. Borbone N, De Marino S, Iorizzi M, Zollo F, Debitus C, Esposito G, Iuvone T. J Nat Prod 2002;65:1206–1209. [PubMed: 12193035]
6. Ridley CP, Faulkner DJ. J Nat Prod 2003;66:1536–1536. [PubMed: 14695791]
7. De Marino S, Zollo F, Iorizzi M, Debitus C. Tetrahedron Lett 1998;39:7611–7614.
8. Aoki S, Watanabe Y, Sanagawa M, Setiawan A, Kotoku N, Kobayashi M. J Am Chem Soc 2006;128:3148–3149. [PubMed: 16522087]
9. McDonald LA, Barbieri LR, Carter GT, Kruppa G, Feng X, Lotvin JA, Siegel MM. Anal Chem 2003;75:2730–2739. [PubMed: 12948143]
10. Breci LA, Tabb DL, Yates JR III, Wysocki VH. Anal Chem 2003;75:1963–1971. [PubMed: 12720328]
11. Nogle LM, Williamson RT, Gerwick WH. J Nat Prod 2001;64:716–719. [PubMed: 11421730]
12. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC. J Org Chem 1996;61:6594–6600. [PubMed: 11667527]
13. Harrigan GG, Luesch H, Yoshida WY, Moore RE, Nagle DG, Paul VJ. J Nat Prod 1999;62:655–658. [PubMed: 10217737]
14. Capon RJ, Ford J, Lacey E, Gill JH, Heiland K, Friedel T. J Nat Prod 2002;65:358–363. [PubMed: 11908978]
15. Matsunaga S, Fusetani N, Konosu S. Tetrahedron Lett 1984;25:5165–5168.
16. Ryu G, Matsunaga S, Fusetani N. Tetrahedron Lett 1994;35:8251–8254.
17. Ryu G, Matsunaga S, Fusetani N. Tetrahedron 1994;50:13409–13416.
18. Li H, Matsunaga S, Fusetani N. J Med Chem 1995;38:338–343. [PubMed: 7830276]
19. Li H, Matsunaga S, Fusetani N. J Nat Prod 1995;59:163–166. [PubMed: 8991950]
20. Gulavita NK, Gunasekera SP, Pomponi SA, Robinson EV. J Org Chem 1992;57:1767–1772.
21. Rashid MA, Gustafson KR, Cartner LK, Shigematsu N, Pannell LK, Boyd MR. J Nat Prod 2001;64:117–121. [PubMed: 11170684]
22. Capon RJ, Rooney F, Murray LM, Collins E, Sim ATR, Rostas JAP, Butler MS, Carroll AR. J Nat Prod 1998;61:660–662. [PubMed: 9599272]
23. Djura P, Faulkner DJ. J Org Chem 1980;45:735–737.
24. Hernández Franco L, Joffe EB, de K, Puricelli L, Tatian M, Seldes AM, Palermo JA. J Nat Prod 1998;61:1130–1132. [PubMed: 9748381]
25. Lee NK, Fenical W, Lindquist N. J Nat Prod 1997;60:697–699. [PubMed: 9249973]
26. Clark WD, Corbett T, Veleriote F, Crews P. J Am Chem Soc 1997;119:9285–9286.
27. Grieco PA, Reilly M. Tetrahedron Lett 1998;39:8925–8928.
28. Marfey P. Carlsberg Res Commun 1984;49:591–596.
29. B'Hymer CJ. Liq Chrom & Rel Technol 2001;24:3085–3094.
30. Sato K, Horibe K, Amano K, Mitsui-Saito M, Hori M, Matsunaga S, Fusetani N, Ozaki H, Karaki H. Toxicon 2001;39:259–264. [PubMed: 10978743]
31. Ratnayake AS, Bugni TS, Feng X, Harper MK, Skalicky JJ, Mohammed KA, Andjelic CD, Barrows LR, Ireland CM. J Nat Prod 2006;69:1582–1586. [PubMed: 17125225]



Figure 1.
Planar structure of corticiamide A (**1**). Bold bonds represent TOCSY correlations, arrows selected HMBC correlations, and lines selected NOE's.



Figure 2.
HR SORI CID mass spectral analysis of major fragments for corticiamide A (**1**).



Figure 3.
Major MS fragments of cyclocinamide B (**2**).

Table 1

NMR data for corticiamide A (**1**) in DMSO-d_6 (600 MHz).

position	δ_C [a]	δ_H (*J* in Hz)	HMBC	position	δ_C [a]	δ_H (*J* in Hz)	HMBC
Alanine				**Cysteic Acid**			
α	47.1	4.29 m	β, C=O	α	51.6	4.60 m	β, C=O
β	19.2	0.91 d (6.0)	α, C=O	β	53.0	2.89 m, 2.95 m	α
NH		8.14	CHO	NH		8.34 br s	
C=O	172.0			C=O	171.7		
CHO	161.2	7.89 br s	α	**Threonine (1)**			
***p*-Bromophenylalanine (1)**				α	53.0	4.86 d (8.6)	
α	52.1	4.67 m	β, γ, C=O	β	69.2	5.22 m	Gly-C=O
β	36.9	2.65 m 2.90 m	γ, δ	γ	17.1	1.06 d (5.0)	α, β
γ	137.7			NH		7.86 br s	
δ, δ′	132.3	7.19 d (8.1)	β, δ′,δ, ζ	C=O	169.4		
ε,ε′	131.4	7.38 d (8.1)	γ, ε′,ε, ζ	***N*-Methylglutamine**			
ζ	120.2			α	54.9	4.93 m	β, γ
NH		8.39 d (8.7)	Ala-C=O	β	25.4	1.55 m	
C=O	170.1			γ	32.0	1.76 m	δC=O
Proline				δC=O	174.0		
α	60.0	4.53 d (6.6)	α, β, C=O	δNH_2		6.67 br s, (7.1)	
β	30.5	2.06 m	γ	*N*Me	30.5	2.93 br s	α, Thr(1)-C=O
γ	25.0	1.83 m	δ	C=O	169.4		
δ	47.4	3.62 br s	β, γ	***p*-Bromophenylalanine (2)**			
C=O	171.8			α	53.0	4.73 m	β, γ C=O
β-Methylisoleucine				β	38.8	2.73 m, 3.01 m	
α	58.9	4.40 d (8.2)	β, γ, δ, C=O	γ	137.6		
β	37.5			δ, δ′	132.5	7.25 d (8.1)	β, δ, ε, ε, ζ
γ	31.8	1.19 m	α, β, ε	ε, ε′	131.4	7.40 d (8.1)	γ, ε′, ζ
δ	23.8	0.82 s		ζ	120.2		
δ	23.8	0.83 s	α, β, γ, ε	NH		7.94 br d (8.2)	*N*-MeGln-C=O
ε	8.7	0.75 t (6.8)	β, γ, δ	C=O	173.2		
NH		7.80 br s		**Threonine (2)**			
C=O	171.2			α	54.7	4.75 m	C=O, *p*BrPhe-C=O
Valine				β	67.4	3.88 m	α
α	58.8	4.12 br t (6.7)	β, γ, C=O	γ	20.3	1.01 d (5.1)	α, β
β	30.9	1.81 m	γ	OH		4.29	α, β, γ
γ	18.5	0.57 d (6.0)	α, β, γ	NH		9.18 d (5.6)	*p*BrPhe C=O
γ	19.7	0.58 d (6.0)	α, β, γ	C=O	171.3		
NH		7.84		***N*-Methylasparagine**			
C=O	173.4			α	56.7	5.36 m	C=O, β, γC=O
Tryptophan				β	35.1	2.34 m, 2.84 m	C=O, γC=O
α	61.5	4.63 m		γC=O	171.5		
β	26.7	2.92 m, 3.11 m	2, 4	γNH_2			
ε′ NH		10.72 br s	3, 4	NMe	29.2	2.60 br s	α, β, Thr(2)-C=O
2	125.0	7.12 br s	3, 4, 9	C=O	169.2		
3	110.5			**Glycine**			
3a	127.8			α	40.5	3.39 m, 4.26 m	C=O
4	119.1	7.59 d (8.1)	3, 7, 9	NH		8.18 br d (7.7)	
5	118.8	6.95 m	4, 8	C=O	169.0		
6	121.5	7.02 m	5, 9				
7	111.8	7.31 d (8.1)	4, 6				
7a	136.7						
NH		8.12 d (7.7)					
C=O	172.0						
Arginine							
α	52.4	4.31 m					

position	δ_C [a]	δ_H (*J* in Hz)	HMBC	position	δ_C [a]	δ_H (*J* in Hz)	HMBC
β	32.1	1.59 m					
γ	28.6	1.28 m					
δ	40.7	2.93 m					
εNH		7.48 br s	φC				
φC	155.5						
φNH_2		6.93 m, 6.95 m	φC, γ				
NH		8.00 br s					
C=O	171.4						

[a] Assignments are from gHMBC, gHSQC, and TOCSY spectra.

Table 2

NMR data for cyclocinamide B (**2**) in DMSO-d_6 (400 MHz).

position	δ_C	δ_H (*J* in Hz)	COSY	TOCSY	HMBC[a]
OH	-	6.00 d (4.0)	-	3	5
1	171.1	-	-	-	-
2	-	7.05 br t (5.0)	4	4, 3	1
3	70.4	4.04 m	4, OH	4, 2, OH	-
4	43.5	3.35 m, 3.48 m	2, 3	3, 2, OH	-
5	171.6	-	-	-	-
6	-	7.87 d (9.9)	7	7, 18	7, 5
7	54.0	4.52 m	6, 18	18, 6	18, 19, 8, 5
8	173.5	-	-	-	-
9	-	7.98 t (6.0)	10	11, 10	8
10	40.8	3.34 s	28, 11	11, 9, 28	-
11	55.2	4.27 m	10, 28	10, 9, 28	29
12	169.4	-	-	-	-
13	-	7.89 d (9.2)	14	14, 15	12
14	50.0	4.56 m	13, 15	15, 13	15, 16, 12
15	37.1	2.26 dd (4.8, 15.6)	11	11, 13	14, 16, 1
15′		2.45 dd (7.4, 15.6)	11	-	14, 16, 1
16	172.6	-	-	-	-
17	-	6.80 brs	17′	17′	16
17′		7.28 brs	17	17	-
18	28.5	2.95	7	7, 6	7, 8, 20, 19, 28
19	110.2	-	-	-	-
20	126.0	7.15 d (1.7)	18, 21	21	19
21	-	11.1 br d (1.7)	20	20	(19, 28)
22	135.5	-	-	-	-
23	114.1	7.28 d (8.4)	26, 24	26, 24	28, 25
24	124.1	7.14 dd (1.8, 8.4)	26, 23	26, 23	28, 26, 25, 22
25	111.8	-	-	-	-
26	121.4	7.63 d (1.8)	24,23	23	19,25, 24, 22
28	129.8	-	-	-	-
28	-	8.09 d (7.6)	11	111, 10	29
29	169.7	-	-	-	-
30	42.9	3.75 m, 3.83 m	31	31	29, 32
31	-	8.57 t (5.8)	30	30	34, 32
32	161.0	-	-	-	-
33	125.2	-	-	-	-
34	112.2	7.02 s	-	-	33, 36, 37, 32
35	107.9	-	-	-	-
36	119.2	-	-	-	-
37	34.1	3.76 s	-	-	33, 34, 36

[a] HMBC correlations from proton(s) to the stated carbons.